Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial.

Ahmed Hanei ElshafieHozaifa Khalil ElsawahMohamed HammadEman Mohamed SweedAhmed Salah SeifMuhammad Mostafa Abdel GhaffarFeisal Mahmoud GodaEsraa M MosalamMahmoud S Abdallah

Published in: Expert review of anti-infective therapy (2022)

The study recommends against using either ivermectin or hydroxychloroquine for treatment of COVID-19 in hospitalized patients with any degree of severity. Clinical trial registration: www.clinicaltrials.gov identifier is: NCT04746365.

Keyphrases

double blind
placebo controlled
clinical trial
phase ii
phase iii
coronavirus disease
sars cov
open label
study protocol
phase ii study
respiratory syndrome coronavirus